Viz.ai has raised a US$100 million funding round at a US$1.2 billion valuation, as per a company press release. The Series D round, which comes as the number of hospitals using the Viz platform surpasses the 1,000 mark, and with patients served in the millions, was led by Tiger Global and Insight Partners. Also joining the round were several of the company’s early backers, including Scale Ventures, Kleiner Perkins, Threshold, GV (formerly Google Ventures), Sozo Ventures, CRV, and Susa.
These new funds will be used to support Viz.ai’s significant growth trajectory, expand the Viz platform to detect and triage additional diseases, and grow its customer base globally, the release adds.
The company continues to expand its reach and innovation in additional disease states. Through its vast network of hospital and health system customers, Viz.ai claims to assist in the care of one patient every 32 seconds.
Over the past year, Viz.ai has launched artificial intelligence (AI)-driven solutions for aortic disease, pulmonary embolism, cerebral aneurysms, and is US Food and Drug Administration (FDA) 510(k)-pending for subdural haematoma. The company was also awarded its first five CE marks in 2021, followed by contracts with several leading hospitals.
“Viz.ai is committed to helping patients get better, faster and more equitable access to life-saving treatments,” said Chris Mansi, Viz.ai co-founder and CEO. “We will continue to invest heavily in cutting-edge technology and services to integrate deeply into the clinical workflow, allowing us to automate disease detection, increase diagnostic rates, and enhance workflows across the entire hub and spoke health system. More patients receive the right treatment, resulting in better patient outcomes and improved financial efficiency for the health system.”
